Prostate cancer sheds the αvβ3 integrin in vivo through exosomes - Krishn, Shiv Ram; Singh, Amrita; Bowler, Nicholas; Duffy, Alexander N.; Friedman, Andrea; Fedele, Carmine; Kurtoglu, Senem; Tripathi, Sushil K.; Wang, Kerith; Hawkins, Adam; Sayeed, Aejaz; Goswami, Chirayu P.; et al. (Matrix biology, 2019)
Keywords: Abiraterone acetate; Adenocarcinoma - blood; Adenocarcinoma - drug therapy; Adenocarcinoma - genetics; Adenocarcinoma - pathology; Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents - pharmacology; Biomarkers, Tumor - blood; Biomarkers, Tumor - genetics; Blood; CD63 antigen; CD9 antigen; Density gradients; Enzalutamide; Exosomes; Exosomes - chemistry; Exosomes - metabolism; Extracellular vesicles; Gene Expression; Humans; Integrin alphaVbeta3 - blood; Integrin alphaVbeta3 - genetics; Localization; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Patients; PC-3 Cells; Phenotypes; Phenylthiohydantoin - analogs & derivatives; Phenylthiohydantoin - pharmacology; Plasma; Plasma exosomes; Prostate cancer; Prostatic Neoplasms - blood; Prostatic Neoplasms - drug therapy; Prostatic Neoplasms - genetics; Prostatic Neoplasms - pathology; Tetraspanin 29 - blood; Tetraspanin 29 - genetics; Tetraspanin 30 - blood; Tetraspanin 30 - genetics; Therapeutic applications; Vesicles; Xenograft Model Antitumor Assays; αvβ3 integrin; Extracellular vesicles; Plasma exosomes; Enzalutamide; αvβ3 integrin; Prostate cancer; Abiraterone acetate